NEWEST 2026 TEST BANK| NUR641E ADVANCED
PATHOPHYSIOLOGY AND PHARMACOLOGY FOR
NURSE EDUCATORS FINAL EXAM PREP WITH
COMPLETE REAL EXAM QUESTIONS AND CORRECT
VERIFIED ANSWERS/ ALREADY GRADED A+
A 72-year-old woman with chronic pain is prescribed an oral opioid. She
reports little pain relief despite adherence. Genetic testing reveals
significantly increased CYP2D6 activity. Which outcome is most likely?
a) Toxicity
b) Tolerance
c) Resistance
d) Dependence - Correct Answer - a) Toxicity
Ultra-rapid CYP2D6 metabolizers convert certain prodrugs such as
codeine into active metabolites more rapidly and extensively, increasing
serum concentrations and risk of opioid toxicity.
A patient receives an intravenous medication with a half-life of 8 hours.
Approximately how long will it take to reach steady state?
a) 8 hr
b) 16 hr
c) 40 hr
d) 80 hr - Correct Answer - c) 40 hr
Most drugs reach steady state after approximately 4–5 half-lives. Five
half-lives × 8 hours = 40 hours.
pg. 1
,A patient with cirrhosis receives a medication with extensive first-pass
metabolism. What pharmacokinetic change is expected?
a) Lower absorption
b) Higher bioavailability
c) Faster excretion
d) Reduced distribution - Correct Answer - b) Higher bioavailability
Hepatic impairment reduces first-pass metabolism, allowing more drug
to enter systemic circulation unchanged.
A 68-year-old male with heart failure with reduced ejection fraction (EF
30%), chronic kidney disease stage 3, and hypertension presents for
follow-up. Current medications include lisinopril, carvedilol,
furosemide, and spironolactone. Laboratory results reveal:
Potassium: 5.8 mEq/L
Creatinine: 2.1 mg/dL (baseline 1.5 mg/dL)
Blood pressure: 118/72 mmHg
Which medication is the most likely contributor to the patient's current
electrolyte abnormality?
a) Furosemide
b) Carvedilol
c) Spironolactone
d) Lisinopril - Correct Answer - c) Spironolactone
Spironolactone is a potassium-sparing aldosterone antagonist. Patients
with chronic kidney disease have reduced potassium excretion and are at
increased risk for hyperkalemia. Although ACE inhibitors can also
elevate potassium, spironolactone is the medication most strongly
pg. 2
,associated with clinically significant hyperkalemia in this setting. The
elevated potassium level of 5.8 mEq/L requires prompt assessment and
possible medication adjustment.
A 74-year-old female taking warfarin for atrial fibrillation develops
melena and an INR of 8.4. Which intervention is most appropriate?
a) Heparin
b) Protamine
c) Vitamin K
d) Aspirin - Correct Answer - c) Vitamin K
Excessive anticoagulation with active bleeding requires reversal.
Vitamin K restores clotting factor synthesis and is indicated for
significant warfarin-associated bleeding.
A 59-year-old diabetic patient develops a persistent cough three weeks
after starting antihypertensive therapy. Which medication is the most
likely cause?
a) Losartan
b) Amlodipine
c) Hydrochlorothiazide
d) Lisinopril - Correct Answer - d) Lisinopril
ACE inhibitors increase bradykinin concentrations, producing a dry,
persistent cough in susceptible patients.
A patient with acute decompensated heart failure arrives with pulmonary
edema. Blood pressure is 186/102 mmHg. Which medication provides
the most rapid symptomatic improvement?
pg. 3
, a) Metoprolol
b) Nitroglycerin
c) Digoxin
d) Atorvastatin - Correct Answer - b) Nitroglycerin
Intravenous nitrates reduce preload and pulmonary congestion rapidly,
improving symptoms in hypertensive acute heart failure.
A patient taking hydrochlorothiazide reports weakness and palpitations.
ECG demonstrates prominent U waves. Which electrolyte abnormality is
most likely?
a) Hypercalcemia
b) Hypernatremia
c) Hypokalemia
d) Hypermagnesemia - Correct Answer - c) Hypokalemia
Thiazide diuretics promote potassium loss. U waves are a classic ECG
finding associated with hypokalemia.
A patient with HFrEF and diabetes is receiving guideline-directed
therapy. Which medication class has demonstrated reductions in both HF
hospitalization and cardiovascular mortality?
a) SGLT2 inhibitor
b) Sulfonylurea
c) Meglitinide
d) DPP-4 inhibitor - Correct Answer - a) SGLT2 inhibitor
SGLT2 inhibitors improve outcomes in heart failure independent of
glucose-lowering effects.
pg. 4